Jazz Pharmaceuticals (JAZZ) Financials

Jazz Pharmaceuticals logo
$239.77 -1.78 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$239.84 +0.07 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Jazz Pharmaceuticals

Annual Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
330 397 488 447 523 239 -330 -224 415 560 -356
Consolidated Net Income / (Loss)
330 397 488 447 523 239 -330 -224 415 560 -356
Net Income / (Loss) Continuing Operations
330 397 488 447 523 239 -330 -224 415 560 -356
Total Pre-Tax Income
436 532 441 529 454 275 -113 -373 298 470 -628
Total Operating Income
508 592 529 615 532 378 170 -66 579 717 -430
Total Gross Profit
1,222 1,383 1,509 1,769 2,034 2,215 2,653 3,119 3,399 3,623 3,764
Total Revenue
1,325 1,488 1,619 1,891 2,162 2,364 3,094 3,659 3,834 4,069 4,268
Operating Revenue
1,325 1,488 1,619 1,891 2,162 2,364 3,094 3,659 3,834 4,069 4,268
Total Cost of Revenue
103 105 110 122 128 149 441 541 436 446 503
Operating Cost of Revenue
103 105 110 122 128 149 441 541 436 446 503
Total Operating Expenses
714 791 980 1,155 1,501 1,837 2,483 3,184 2,820 2,907 4,195
Selling, General & Admin Expense
449 503 544 684 737 854 1,452 1,417 1,343 1,385 1,809
Research & Development Expense
135 186 283 227 410 587 506 1,035 869 894 1,731
Amortization Expense
98 102 152 201 355 260 526 599 608 627 655
Total Other Income / (Expense), net
-72 -59 -88 -85 -78 -103 -283 -307 -281 -246 -198
Interest & Investment Income
-57 -62 -78 -79 -72 -100 -279 -288 -289 -238 -195
Other Income / (Expense), net
1.45 3.37 -9.97 -6.88 -5.81 -3.27 -4.35 -19 8.79 -8.18 -2.57
Income Tax Expense
106 135 -48 80 -73 34 216 -159 -120 -91 -272
Other Gains / (Losses), net
0.00 -0.38 -1.01 -2.20 -4.09 -2.96 -0.71 -9.92 -3.01 -1.66 -0.73
Basic Earnings per Share
$5.38 $6.56 $8.13 $7.45 $9.22 $4.28 ($5.52) ($3.58) $6.55 $9.06 ($5.84)
Weighted Average Basic Shares Outstanding
61.23M 60.50M 60.02M 59.98M 56.75M 55.71M 59.69M 62.54M 63.29M 61.84M 60.98M
Diluted Earnings per Share
$5.23 $6.41 $7.96 $7.30 $9.09 $4.22 ($5.52) ($3.58) $6.10 $8.65 ($5.84)
Weighted Average Diluted Shares Outstanding
63.04M 61.87M 61.32M 61.22M 57.55M 56.52M 59.69M 62.54M 72.07M 66.01M 60.98M
Weighted Average Basic & Diluted Shares Outstanding
61.30M 60.50M 60M 60M 56.13M 56.33M 61.74M 63.33M 62.35M 60.73M 61.56M

Quarterly Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-15 169 215 191 -93 -719 251 203 293 193 -483
Consolidated Net Income / (Loss)
-15 169 215 191 -93 -719 251 203 293 193 -483
Net Income / (Loss) Continuing Operations
-15 169 215 191 -93 -719 251 203 293 193 -483
Total Pre-Tax Income
-1.60 138 201 133 -110 -736 9.00 208 299 211 -459
Total Operating Income
66 199 260 191 -56 -686 58 255 337 248 -413
Total Gross Profit
806 914 943 959 793 929 997 1,044 935 1,092 1,132
Total Revenue
902 1,024 1,055 1,088 898 1,046 1,126 1,198 1,069 1,208 1,243
Operating Revenue
902 1,024 1,055 1,088 898 1,046 1,126 1,198 1,069 1,208 1,243
Total Cost of Revenue
95 110 112 129 105 116 129 154 134 116 111
Operating Cost of Revenue
95 110 112 129 105 116 129 154 134 116 111
Total Operating Expenses
740 714 683 769 849 1,616 940 790 598 844 1,546
Selling, General & Admin Expense
352 339 326 369 514 358 531 406 353 389 408
Research & Development Expense
233 221 200 241 181 1,095 241 214 196 285 966
Amortization Expense
156 155 157 159 154 162 168 170 172 170 172
Other Special Charges / (Income)
- - - - 0.00 0.00 0.00 - -123 0.00 0.00
Total Other Income / (Expense), net
-68 -62 -59 -58 -54 -49 -49 -46 -37 -37 -46
Interest & Investment Income
-66 -62 -59 -51 -54 -47 -49 -45 -40 -37 -46
Other Income / (Expense), net
-1.69 0.51 -0.70 -6.30 -0.20 -1.80 0.10 -0.66 2.50 -0.10 0.00
Income Tax Expense
12 -31 -15 -58 -18 -17 -242 4.96 6.10 18 25
Other Gains / (Losses), net
-1.35 -0.01 -0.29 -0.02 -0.50 -0.10 0.00 -0.06 0.00 -0.10 0.00
Basic Earnings per Share
($0.23) $2.68 $3.50 $3.11 ($1.52) ($11.74) $4.14 $3.28 $4.73 $3.05 ($7.48)
Weighted Average Basic Shares Outstanding
62.54M 62.88M 61.41M 61.84M 61M 61.20M 60.70M 60.98M 61.90M 63.20M 64.70M
Diluted Earnings per Share
($0.23) $2.49 $3.42 $2.97 ($1.52) ($11.74) $4.08 $3.34 $4.43 $2.78 ($7.48)
Weighted Average Diluted Shares Outstanding
62.54M 69.63M 63.17M 66.01M 61M 61.20M 61.60M 60.98M 66.10M 69.40M 64.70M
Weighted Average Basic & Diluted Shares Outstanding
63.04M 61.75M 60.45M 60.73M 61.63M 60.66M 60.77M 61.56M 62.74M 64.91M 64.19M

Annual Cash Flow Statements for Jazz Pharmaceuticals

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
305 -623 20 -75 328 420 -466 290 625 907 -1,021
Net Cash From Operating Activities
532 592 693 799 776 900 779 1,272 1,092 1,396 1,356
Net Cash From Continuing Operating Activities
532 592 693 799 776 900 779 1,272 1,092 1,396 1,356
Net Income / (Loss) Continuing Operations
330 397 488 447 523 239 -330 -224 415 560 -356
Consolidated Net Income / (Loss)
330 397 488 447 523 239 -330 -224 415 560 -356
Depreciation Expense
9.89 12 13 15 15 19 27 30 30 33 42
Amortization Expense
121 124 182 245 355 260 526 599 608 627 655
Non-Cash Adjustments To Reconcile Net Income
139 122 209 159 288 618 550 1,164 503 461 1,442
Changes in Operating Assets and Liabilities, net
-67 -62 -199 -68 -405 -235 5.66 -297 -465 -285 -426
Net Cash From Investing Activities
-2.26 -1,751 -269 -394 -155 -1,008 -5,212 -446 -163 -508 -1,510
Net Cash From Continuing Investing Activities
-2.26 -1,751 -269 -394 -155 -1,008 -5,212 -446 -163 -508 -1,510
Purchase of Property, Plant & Equipment
-36 -9.69 -29 -20 -40 -15 -28 -29 -24 -38 -917
Acquisitions
0.00 -1,676 -85 -111 -197 -364 -6,253 -469 -19 -10 -151
Purchase of Investments
0.00 -132 -385 -1,166 -917 -2,398 -27 -61 -390 -1,305 -1,830
Sale of Property, Plant & Equipment
- 0.00 0.00 48 14 - - - 0.00 0.00 28
Sale and/or Maturity of Investments
0.00 67 230 855 985 1,755 1,095 60 270 845 1,360
Net Cash From Financing Activities
-214 541 -409 -479 -294 528 3,971 -529 -305 21 -873
Net Cash From Continuing Financing Activities
-214 541 -409 -479 -294 528 3,971 -529 -305 21 -873
Repayment of Debt
-1,066 -178 -886 -32 -33 -890 -1,321 -582 -31 -612 -781
Repurchase of Common Equity
-62 -278 -99 -524 -301 -147 0.00 -0.05 -270 -311 -125
Issuance of Debt
899 995 559 0.00 0.00 1,481 5,191 0.00 0.00 981 0.00
Issuance of Common Equity
41 24 32 93 58 100 135 98 46 21 108
Other Financing Activities, net
-26 -21 -15 -17 -17 -17 -36 -45 -51 -58 -75
Other Net Changes in Cash
- - 5.05 - - - -3.21 -6.22 1.14 - 6.56
Cash Interest Paid
40 40 45 43 43 42 138 271 333 315 249
Cash Income Taxes Paid
146 160 174 164 184 227 271 95 178 115 122

Quarterly Cash Flow Statements for Jazz Pharmaceuticals

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-63 -88 862 195 -551 -672 136 66 452 -225 417
Net Cash From Operating Activities
267 331 399 399 430 89 475 363 408 416 506
Net Cash From Continuing Operating Activities
267 331 399 399 430 89 475 363 408 416 506
Net Income / (Loss) Continuing Operations
-15 169 215 191 -93 -718 251 203 293 193 -483
Consolidated Net Income / (Loss)
-15 169 215 191 -93 -718 251 203 293 193 -483
Depreciation Expense
7.65 7.81 7.78 9.51 10 12 9.88 9.43 9.10 9.10 7.10
Amortization Expense
156 155 157 159 154 162 168 170 172 170 172
Non-Cash Adjustments To Reconcile Net Income
132 105 113 128 114 1,033 189 100 12 177 843
Changes in Operating Assets and Liabilities, net
-14 -105 -94 -89 244 -400 -144 -120 -78 -133 -32
Net Cash From Investing Activities
-272 -257 214 -193 -169 -641 -328 -372 123 355 -1,084
Net Cash From Continuing Investing Activities
-272 -257 214 -193 -169 -641 -328 -372 123 355 -1,084
Purchase of Property, Plant & Equipment
-6.90 -7.09 -11 -13 -14 -871 -15 -17 -97 -18 -847
Purchase of Investments
-375 -330 -130 -470 -440 -240 -640 -510 -500 -270 -740
Sale and/or Maturity of Investments
120 80 355 290 310 470 400 180 520 720 500
Net Cash From Financing Activities
-57 -161 246 -8.28 -814 -125 -11 75 -79 -995 994
Net Cash From Continuing Financing Activities
-57 -161 246 -8.28 -814 -125 -11 75 -79 -995 994
Repayment of Debt
-7.75 -7.75 -583 -13 -758 -7.75 -7.75 -7.75 -7.80 -1,008 -13
Repurchase of Common Equity
- - -150 - - - - - - - -225
Issuance of Common Equity
0.49 11 0.02 9.20 12 10 0.73 85 33 23 11
Other Financing Activities, net
-49 -2.85 -1.61 -4.01 -67 -2.25 -3.81 -2.00 -104 -9.50 -4.80

Annual Balance Sheets for Jazz Pharmaceuticals

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
3,333 4,800 5,124 5,203 5,539 6,536 12,299 10,835 11,393 12,012 11,659
Total Current Assets
1,258 748 968 1,234 1,630 2,840 2,611 2,606 3,435 4,629 4,166
Cash & Equivalents
989 366 386 310 637 1,058 591 881 1,506 2,413 1,392
Short-Term Investments
0.00 60 215 515 440 1,075 - 0.00 120 580 1,050
Accounts Receivable
210 234 224 264 356 396 563 651 706 717 831
Inventories, net
19 34 43 53 79 95 1,073 714 597 480 417
Prepaid Expenses
21 25 23 25 39 62 131 92 185 177 153
Other Current Assets
19 29 77 68 79 152 252 267 321 262 324
Plant, Property, & Equipment, net
86 107 170 200 132 128 257 228 170 173 200
Total Noncurrent Assets
1,989 3,945 3,985 3,769 3,777 3,568 9,430 8,001 7,788 7,210 7,293
Goodwill
657 894 948 928 920 958 1,828 1,693 1,753 1,716 1,829
Intangible Assets
1,186 3,012 2,979 2,731 2,441 2,195 7,152 5,794 5,418 4,756 4,430
Noncurrent Deferred & Refundable Income Taxes
130 15 35 58 221 255 311 376 478 560 869
Other Noncurrent Operating Assets
9.27 14 16 43 187 155 127 128 133 168 158
Other Noncurrent Nonoperating Assets
7.21 9.74 7.67 9.59 7.43 5.24 12 9.25 6.48 9.49 7.60
Total Liabilities & Shareholders' Equity
3,333 4,800 5,124 5,203 5,539 6,536 12,299 10,835 11,393 12,012 11,659
Total Liabilities
1,734 2,923 2,411 2,446 2,428 2,876 8,333 7,750 7,656 7,919 7,341
Total Current Liabilities
227 257 294 345 364 654 809 933 1,537 1,039 2,243
Short-Term Debt
38 36 41 33 33 246 31 31 605 31 1,030
Accounts Payable
22 22 24 41 46 27 100 91 103 78 122
Accrued Expenses
164 193 199 265 270 353 666 803 794 911 1,034
Current Deferred & Payable Income Tax Liabilities
1.81 4.51 22 1.20 11 25 9.61 7.72 35 19 56
Total Noncurrent Liabilities
1,507 2,665 2,117 2,101 2,063 2,222 7,524 6,816 6,120 6,880 5,098
Long-Term Debt
1,151 1,994 1,540 1,563 1,574 1,849 6,019 5,693 5,108 6,078 4,328
Noncurrent Deferred & Payable Income Tax Liabilities
283 557 383 309 224 130 1,301 944 848 677 595
Other Noncurrent Operating Liabilities
69 113 177 219 261 241 204 179 164 126 175
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,599 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Total Preferred & Common Equity
1,599 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Total Common Equity
1,599 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Common Stock
1,563 1,665 1,935 2,114 2,266 2,634 3,535 3,477 3,700 3,914 4,241
Retained Earnings
303 529 918 841 1,068 1,160 830 734 879 1,127 646
Accumulated Other Comprehensive Income / (Loss)
-267 -317 -141 -198 -223 -134 -400 -1,126 -842 -948 -569
Other Equity Adjustments
0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.60

Quarterly Balance Sheets for Jazz Pharmaceuticals

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
11,261 11,204 11,327 11,362 12,256 11,535 10,944 11,356 11,860 11,081 11,998
Total Current Assets
3,010 3,246 3,540 3,682 4,390 4,128 3,350 3,756 4,583 3,968 4,613
Cash & Equivalents
1,282 1,336 1,443 1,356 2,218 1,862 1,190 1,326 1,844 1,620 2,036
Short-Term Investments
80 250 375 625 400 710 480 720 1,030 580 820
Accounts Receivable
610 628 707 698 724 653 714 764 836 881 874
Inventories, net
657 612 577 543 539 493 505 483 438 443 454
Prepaid Expenses
107 110 123 134 155 150 164 147 150 200 171
Other Current Assets
272 310 315 326 354 260 298 315 285 245 258
Plant, Property, & Equipment, net
229 222 166 169 176 179 185 189 203 212 225
Total Noncurrent Assets
8,021 7,736 7,621 7,511 7,689 7,228 7,409 7,412 7,073 6,901 7,160
Goodwill
1,743 1,705 1,739 1,736 1,805 1,760 1,844 1,827 1,805 1,800 1,803
Intangible Assets
5,706 5,418 5,235 5,079 5,144 4,718 4,769 4,566 4,204 4,030 4,174
Noncurrent Deferred & Refundable Income Taxes
430 464 508 545 583 575 603 846 907 926 999
Other Noncurrent Operating Assets
135 141 132 145 152 166 184 164 151 138 178
Other Noncurrent Nonoperating Assets
7.87 7.17 5.78 5.74 4.40 9.00 8.52 8.03 7.10 6.60 6.10
Total Liabilities & Shareholders' Equity
11,261 11,204 11,327 11,362 12,256 11,535 10,944 11,356 11,860 11,081 11,998
Total Liabilities
7,735 7,715 7,631 7,599 8,085 7,360 7,238 7,397 7,327 6,279 7,806
Total Current Liabilities
945 1,573 1,562 1,556 1,030 1,223 2,071 2,274 2,247 2,231 2,533
Short-Term Debt
31 605 605 606 31 31 1,028 1,029 1,031 1,016 1,017
Accounts Payable
98 110 81 97 85 96 89 152 100 129 380
Accrued Expenses
748 770 827 801 859 1,064 875 1,002 1,022 1,030 1,076
Current Deferred & Payable Income Tax Liabilities
68 89 49 52 55 32 79 91 94 56 59
Total Noncurrent Liabilities
6,790 6,141 6,068 6,043 7,055 6,137 5,167 5,123 5,081 4,048 5,273
Long-Term Debt
5,687 5,111 5,105 5,101 6,081 5,336 4,336 4,332 4,324 3,335 4,552
Noncurrent Deferred & Payable Income Tax Liabilities
911 841 810 775 792 671 682 629 548 529 506
Other Noncurrent Operating Liabilities
192 189 154 167 182 130 149 162 209 185 215
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
3,526 3,489 3,696 3,763 4,171 4,175 3,706 3,959 4,532 4,802 4,192
Total Preferred & Common Equity
3,526 3,489 3,696 3,763 4,171 4,175 3,706 3,959 4,532 4,802 4,192
Total Common Equity
3,526 3,489 3,696 3,763 4,171 4,175 3,706 3,959 4,532 4,802 4,192
Common Stock
3,580 3,640 3,714 3,779 3,838 3,925 4,000 4,086 4,244 4,332 4,414
Retained Earnings
812 884 864 871 936 1,035 191 443 939 1,132 424
Accumulated Other Comprehensive Income / (Loss)
-867 -1,035 -882 -888 -603 -786 -486 -570 -651 -663 -647
Other Equity Adjustments
0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.60 0.60 0.60

Annual Metrics And Ratios for Jazz Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
12.95% 12.32% 8.79% 16.82% 14.32% 9.34% 30.91% 18.26% 4.78% 6.12% 4.88%
EBITDA Growth
82.12% 14.13% -2.31% 21.65% 3.23% -27.17% 10.01% -24.15% 125.00% 11.62% -80.75%
EBIT Growth
149.51% 16.75% -12.80% 17.17% -13.39% -28.82% -55.73% -150.95% 794.76% 20.61% -161.09%
NOPAT Growth
419.30% 14.89% 32.78% -10.98% 18.47% -46.29% -64.10% -138.48% 1,869.04% 5.48% -135.19%
Net Income Growth
474.84% 20.42% 22.94% -8.35% 17.06% -54.41% -238.16% 32.03% 285.14% 35.02% -163.58%
EPS Growth
462.37% 22.56% 24.18% -8.29% 24.52% -53.58% -230.81% 35.14% 270.39% 41.80% -167.51%
Operating Cash Flow Growth
30.50% 11.36% 17.00% 15.27% -2.82% 15.87% -13.47% 63.39% -14.15% 27.83% -2.88%
Free Cash Flow Firm Growth
182.64% -310.02% 130.02% 84.87% -26.66% -30.81% -1,726.79% 125.48% -36.84% 61.23% -122.30%
Invested Capital Growth
-10.30% 93.81% 6.17% -4.50% 3.23% -0.46% 160.24% -15.86% -1.29% -7.89% 0.38%
Revenue Q/Q Growth
0.97% 3.89% 2.52% 2.16% 5.12% 3.67% 8.08% 2.10% 1.05% 1.91% 2.64%
EBITDA Q/Q Growth
-4.69% 9.83% 0.27% 4.48% -4.53% 6.79% -4.73% -37.68% 50.65% 4.73% 43.72%
EBIT Q/Q Growth
-4.35% 11.57% -5.48% 7.61% -19.10% 43.36% -43.67% -137.56% 209.71% 8.02% 13.82%
NOPAT Q/Q Growth
0.08% 9.01% 34.42% -15.40% -10.94% 16.82% 119.13% -126.50% 501.57% 13.12% 12.91%
Net Income Q/Q Growth
0.35% 9.35% 31.03% -13.99% -14.04% 33.16% -104.89% -1,099.02% 418.84% 20.93% 3.35%
EPS Q/Q Growth
-1.51% 9.95% 31.35% -13.71% -13.01% 33.54% -117.32% -867.57% 617.65% 22.18% 5.96%
Operating Cash Flow Q/Q Growth
-2.66% 11.47% 3.57% 1.72% -14.37% 12.29% -1.08% 14.82% -13.79% 19.85% -2.59%
Free Cash Flow Firm Q/Q Growth
-7.25% -2.89% 19.66% 4.49% -23.69% 8.19% 14.17% -32.49% 964.67% 108.02% -778.07%
Invested Capital Q/Q Growth
-3.41% 0.23% 2.70% -0.78% 1.48% 2.10% -1.27% 4.72% 2.70% -6.01% -0.53%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
92.26% 92.92% 93.19% 93.57% 94.08% 93.70% 85.76% 85.23% 88.64% 89.05% 88.21%
EBITDA Margin
48.34% 49.12% 44.11% 45.94% 41.48% 27.63% 23.22% 14.89% 31.98% 33.63% 6.17%
Operating Margin
38.36% 39.76% 32.67% 32.52% 24.63% 16.00% 5.50% -1.79% 15.09% 17.61% -10.08%
EBIT Margin
38.47% 39.99% 32.06% 32.15% 24.36% 15.86% 5.36% -2.31% 15.32% 17.41% -10.14%
Profit (Net Income) Margin
24.87% 26.67% 30.14% 23.64% 24.21% 10.10% -10.65% -6.12% 10.82% 13.77% -8.35%
Tax Burden Percent
75.59% 74.53% 110.59% 84.44% 115.20% 86.74% 292.16% 60.10% 139.24% 119.09% 56.72%
Interest Burden Percent
85.53% 89.48% 85.01% 87.09% 86.28% 73.40% -68.00% 440.95% 50.72% 66.39% 145.07%
Effective Tax Rate
24.41% 25.40% -10.82% 15.14% -16.10% 12.18% 0.00% 0.00% -40.25% -19.44% 0.00%
Return on Invested Capital (ROIC)
20.28% 16.78% 16.38% 14.48% 17.28% 9.16% 1.83% -0.53% 10.31% 11.40% -4.17%
ROIC Less NNEP Spread (ROIC-NNEP)
6.92% 11.79% 8.72% 5.88% 2.53% -29.81% -14.78% -4.00% 1.41% 3.17% -6.00%
Return on Net Nonoperating Assets (RNNOA)
1.91% 6.06% 4.88% 1.86% 0.55% -2.11% -10.48% -5.83% 1.85% 2.91% -4.29%
Return on Equity (ROE)
22.19% 22.83% 21.26% 16.35% 17.84% 7.05% -8.65% -6.36% 12.16% 14.31% -8.47%
Cash Return on Invested Capital (CROIC)
31.14% -47.08% 10.39% 19.09% 14.10% 9.62% -87.13% 16.69% 11.61% 19.62% -4.55%
Operating Return on Assets (OROA)
15.28% 14.63% 10.46% 11.77% 9.80% 6.21% 1.76% -0.73% 5.28% 6.05% -3.66%
Return on Assets (ROA)
9.88% 9.76% 9.83% 8.66% 9.74% 3.95% -3.50% -1.94% 3.73% 4.79% -3.01%
Return on Common Equity (ROCE)
22.19% 22.83% 21.26% 16.35% 17.84% 7.05% -8.65% -6.36% 12.16% 14.31% -8.47%
Return on Equity Simple (ROE_SIMPLE)
20.61% 21.14% 17.98% 16.21% 16.82% 6.52% -8.31% -7.26% 11.10% 13.68% 0.00%
Net Operating Profit after Tax (NOPAT)
384 441 586 522 618 332 119 -46 811 856 -301
NOPAT Margin
29.00% 29.66% 36.21% 27.59% 28.59% 14.05% 3.85% -1.25% 21.16% 21.04% -7.06%
Net Nonoperating Expense Percent (NNEP)
13.36% 4.99% 7.66% 8.61% 14.75% 38.97% 16.61% 3.47% 8.90% 8.23% 1.83%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -0.52% 8.59% 8.39% -3.11%
Cost of Revenue to Revenue
7.74% 7.08% 6.81% 6.43% 5.92% 6.30% 14.24% 14.77% 11.36% 10.95% 11.79%
SG&A Expenses to Revenue
33.90% 33.80% 33.62% 36.15% 34.09% 36.14% 46.92% 38.72% 35.03% 34.05% 42.40%
R&D to Revenue
10.21% 12.50% 17.51% 11.98% 18.95% 24.82% 16.34% 28.27% 22.66% 21.97% 40.55%
Operating Expenses to Revenue
53.90% 53.16% 60.52% 61.06% 69.46% 77.70% 80.25% 87.02% 73.55% 71.43% 98.29%
Earnings before Interest and Taxes (EBIT)
510 595 519 608 527 375 166 -85 587 708 -433
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
640 731 714 869 897 653 718 545 1,226 1,369 263
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.41 3.48 2.98 2.71 2.71 2.51 1.98 3.25 2.07 1.82 2.39
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 18.16 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
6.52 4.39 4.99 3.95 3.91 3.89 2.53 2.74 2.02 1.83 2.42
Price to Earnings (P/E)
26.23 16.46 16.55 16.72 16.14 38.54 0.00 0.00 18.67 13.29 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
3.81% 6.08% 6.04% 5.98% 6.20% 2.59% 0.00% 0.00% 5.36% 7.52% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.94 2.34 2.46 2.34 2.47 2.53 1.41 1.88 1.51 1.47 1.83
Enterprise Value to Revenue (EV/Rev)
6.68 5.47 5.59 4.36 4.15 3.87 4.30 4.06 3.09 2.60 3.10
Enterprise Value to EBITDA (EV/EBITDA)
13.81 11.13 12.68 9.50 10.01 14.02 18.50 27.30 9.65 7.72 50.27
Enterprise Value to EBIT (EV/EBIT)
17.35 13.67 17.45 13.57 17.04 24.43 80.09 0.00 20.14 14.91 0.00
Enterprise Value to NOPAT (EV/NOPAT)
23.02 18.43 15.45 15.81 14.52 27.58 111.50 0.00 14.58 12.34 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
16.63 13.73 13.06 10.33 11.56 10.18 17.07 11.69 10.83 7.57 9.77
Enterprise Value to Free Cash Flow (EV/FCFF)
14.99 0.00 24.34 12.00 17.80 26.25 0.00 10.28 12.95 7.17 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.74 1.08 0.58 0.58 0.52 0.57 1.53 1.86 1.53 1.49 1.24
Long-Term Debt to Equity
0.72 1.06 0.57 0.57 0.51 0.51 1.52 1.85 1.37 1.48 1.00
Financial Leverage
0.28 0.51 0.56 0.32 0.22 0.07 0.71 1.46 1.31 0.92 0.72
Leverage Ratio
2.25 2.34 2.16 1.89 1.83 1.78 2.47 3.28 3.26 2.99 2.81
Compound Leverage Factor
1.92 2.09 1.84 1.64 1.58 1.31 -1.68 14.47 1.65 1.98 4.08
Debt to Total Capital
42.64% 51.95% 36.82% 36.67% 34.06% 36.40% 60.41% 64.97% 60.45% 59.87% 55.37%
Short-Term Debt to Total Capital
1.35% 0.92% 0.95% 0.77% 0.71% 4.28% 0.31% 0.35% 6.40% 0.30% 10.64%
Long-Term Debt to Total Capital
41.29% 51.03% 35.87% 35.90% 33.36% 32.12% 60.10% 64.62% 54.05% 59.57% 44.73%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
57.36% 48.05% 63.18% 63.33% 65.94% 63.60% 39.59% 35.03% 39.55% 40.13% 44.63%
Debt to EBITDA
1.86 2.78 2.21 1.84 1.79 3.21 8.42 10.50 4.66 4.46 20.34
Net Debt to EBITDA
0.31 2.19 1.37 0.89 0.59 -0.06 7.60 8.89 3.33 2.28 11.07
Long-Term Debt to EBITDA
1.80 2.73 2.16 1.80 1.76 2.83 8.38 10.45 4.17 4.44 16.43
Debt to NOPAT
3.09 4.60 2.70 3.06 2.60 6.31 50.76 -124.80 7.04 7.14 -17.79
Net Debt to NOPAT
0.52 3.63 1.67 1.48 0.86 -0.11 45.79 -105.58 5.04 3.64 -9.68
Long-Term Debt to NOPAT
3.00 4.52 2.63 3.00 2.55 5.57 50.50 -124.12 6.29 7.10 -14.37
Altman Z-Score
4.39 2.34 3.07 3.01 3.34 3.12 1.13 1.37 1.42 1.59 1.36
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.55 2.91 3.29 3.57 4.47 4.34 3.23 2.79 2.24 4.46 1.86
Quick Ratio
5.29 2.56 2.81 3.15 3.93 3.87 1.43 1.64 1.52 3.57 1.46
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
590 -1,239 372 688 504 349 -5,676 1,446 914 1,473 -329
Operating Cash Flow to CapEx
1,479.35% 6,115.32% 2,394.08% 0.00% 2,994.68% 5,996.05% 2,816.49% 4,379.18% 4,557.24% 3,666.69% 152.57%
Free Cash Flow to Firm to Interest Expense
35.08 -1,941.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
31.64 928.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
29.50 913.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.40 0.37 0.33 0.37 0.40 0.39 0.33 0.32 0.35 0.35 0.36
Accounts Receivable Turnover
6.69 6.70 7.06 7.75 6.98 6.28 6.45 6.02 5.65 5.72 5.52
Inventory Turnover
4.14 3.94 2.85 2.53 1.94 1.71 0.75 0.61 0.66 0.83 1.12
Fixed Asset Turnover
18.41 15.41 11.66 10.21 13.03 18.22 16.08 15.09 19.28 23.72 22.87
Accounts Payable Turnover
4.37 4.77 4.71 3.74 2.96 4.10 6.93 5.66 4.50 4.94 5.03
Days Sales Outstanding (DSO)
54.56 54.45 51.68 47.10 52.33 58.10 56.61 60.59 64.60 63.80 66.18
Days Inventory Outstanding (DIO)
88.09 92.65 128.02 144.45 187.68 213.24 483.67 603.29 549.33 441.18 325.41
Days Payable Outstanding (DPO)
83.54 76.58 77.48 97.55 123.16 89.07 52.69 64.51 81.08 73.96 72.50
Cash Conversion Cycle (CCC)
59.11 70.52 102.22 93.99 116.85 182.28 487.59 599.37 532.86 431.03 319.09
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,791 3,471 3,685 3,520 3,633 3,617 9,412 7,919 7,817 7,200 7,227
Invested Capital Turnover
0.70 0.57 0.45 0.52 0.60 0.65 0.48 0.42 0.49 0.54 0.59
Increase / (Decrease) in Invested Capital
-206 1,680 214 -166 114 -17 5,795 -1,492 -102 -617 27
Enterprise Value (EV)
8,844 8,134 9,052 8,249 8,975 9,158 13,290 14,874 11,830 10,561 13,246
Market Capitalization
8,644 6,530 8,072 7,477 8,445 9,196 7,831 10,031 7,744 7,445 10,330
Book Value per Share
$26.00 $31.35 $45.26 $45.71 $54.99 $65.69 $64.51 $49.01 $59.36 $67.72 $71.07
Tangible Book Value per Share
($3.97) ($33.87) ($20.24) ($14.95) ($4.42) $9.09 ($81.58) ($69.90) ($54.55) ($39.34) ($31.93)
Total Capital
2,787 3,907 4,294 4,354 4,718 5,755 10,015 8,810 9,450 10,202 9,677
Total Debt
1,188 2,030 1,581 1,596 1,607 2,095 6,050 5,724 5,713 6,109 5,358
Total Long-Term Debt
1,151 1,994 1,540 1,563 1,574 1,849 6,019 5,693 5,108 6,078 4,328
Net Debt
200 1,604 980 772 530 -38 5,458 4,843 4,087 3,116 2,916
Capital Expenditures (CapEx)
36 9.69 29 -28 26 15 28 29 24 38 889
Debt-free, Cash-free Net Working Capital (DFCFNWC)
80 101 114 97 222 299 1,242 822 877 629 512
Debt-free Net Working Capital (DFNWC)
1,069 527 715 922 1,299 2,432 1,833 1,704 2,504 3,621 2,953
Net Working Capital (NWC)
1,031 491 674 889 1,266 2,186 1,802 1,673 1,899 3,590 1,924
Net Nonoperating Expense (NNE)
55 45 98 75 95 93 449 178 397 296 55
Net Nonoperating Obligations (NNO)
192 1,594 972 762 522 -43 5,446 4,834 4,080 3,106 2,909
Total Depreciation and Amortization (D&A)
131 136 195 261 370 278 552 629 639 660 696
Debt-free, Cash-free Net Working Capital to Revenue
6.03% 6.77% 7.04% 5.14% 10.26% 12.67% 40.13% 22.48% 22.88% 15.45% 11.99%
Debt-free Net Working Capital to Revenue
80.66% 35.40% 44.17% 48.75% 60.10% 102.90% 59.24% 46.56% 65.30% 89.00% 69.21%
Net Working Capital to Revenue
77.82% 32.98% 41.66% 46.99% 58.55% 92.48% 58.24% 45.72% 49.52% 88.24% 45.07%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$5.38 $6.56 $8.13 $7.45 $9.22 $4.28 ($5.52) ($3.58) $6.55 $9.06 ($5.84)
Adjusted Weighted Average Basic Shares Outstanding
61.23M 60.50M 60.02M 59.98M 56.75M 55.71M 59.69M 62.54M 63.29M 61.84M 60.98M
Adjusted Diluted Earnings per Share
$5.23 $6.41 $7.96 $7.30 $9.09 $4.22 ($5.52) ($3.58) $6.10 $8.65 ($5.84)
Adjusted Weighted Average Diluted Shares Outstanding
63.04M 61.87M 61.32M 61.22M 57.55M 56.52M 59.69M 62.54M 72.07M 66.01M 60.98M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
61.18M 59.74M 59.80M 57.06M 56.13M 56.33M 61.74M 63.33M 62.35M 60.73M 61.56M
Normalized Net Operating Profit after Tax (NOPAT)
408 441 370 558 373 452 119 48 405 502 -301
Normalized NOPAT Margin
30.80% 29.66% 22.87% 29.52% 17.24% 19.11% 3.85% 1.30% 10.56% 12.33% -7.06%
Pre Tax Income Margin
32.91% 35.78% 27.25% 28.00% 21.02% 11.64% -3.65% -10.19% 7.77% 11.56% -14.71%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
30.31 932.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
22.85 691.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
28.17 917.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
20.71 676.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
18.68% 70.13% 20.25% 117.13% 57.60% 61.41% 0.00% -0.02% 65.03% 55.60% -35.10%

Quarterly Metrics And Ratios for Jazz Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 61,560,350.00 62,742,820.00 64,914,577.00
DEI Adjusted Shares Outstanding
- - - - - - - - 61,560,350.00 62,742,820.00 64,914,577.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 4.76 3.07 -7.45
Growth Metrics
- - - - - - - - - - -
Revenue Growth
1.03% 6.95% 8.52% 7.53% -0.46% 2.14% 6.74% 10.09% 19.06% 15.55% 10.38%
EBITDA Growth
-20.48% 15.30% 27.33% 21.25% -52.27% -241.65% -44.47% 22.71% 378.84% 183.08% -199.41%
EBIT Growth
-50.09% 28.79% 51.75% 39.91% -186.97% -444.18% -77.80% 37.62% 704.46% 136.05% -817.71%
NOPAT Growth
-71.23% 19.19% 9.81% 45.29% -184.42% -297.10% 473.59% -9.22% 942.67% 147.23% -118.02%
Net Income Growth
-121.06% 61.40% 46.48% 102.98% -533.06% -526.22% 16.91% 6.45% 416.86% 126.83% -292.28%
EPS Growth
-122.12% 63.82% 59.81% 112.14% -560.87% -571.49% 19.30% 12.46% 391.45% 123.68% -283.33%
Operating Cash Flow Growth
-16.68% 11.65% 29.80% 138.19% 60.83% -73.18% 19.03% -9.05% -5.03% 368.13% 6.61%
Free Cash Flow Firm Growth
-74.05% -17.78% 12.41% 206.58% 69.84% -161.46% 765.51% -75.18% -50.95% 272.51% -96.10%
Invested Capital Growth
-3.76% -4.96% 0.64% -7.89% -8.19% -1.21% -5.15% 0.38% 0.63% -6.02% -5.06%
Revenue Q/Q Growth
-10.87% 13.51% 3.04% 3.15% -17.49% 16.47% 7.69% 6.38% -10.77% 13.04% 2.87%
EBITDA Q/Q Growth
-21.70% 59.28% 17.01% -16.92% -69.18% -572.73% 145.87% 83.61% 20.20% -17.93% -154.89%
EBIT Q/Q Growth
-51.07% 209.93% 29.79% -28.91% -130.41% -1,126.61% 108.37% 340.67% 33.57% -26.84% -266.63%
NOPAT Q/Q Growth
-75.40% 425.99% 14.47% -1.91% -114.29% -1,128.07% 433.12% -84.48% 32.70% -31.19% -227.53%
Net Income Q/Q Growth
-115.53% 1,253.15% 27.58% -11.13% -148.42% -676.38% 134.99% -19.08% 44.06% -34.22% -350.73%
EPS Q/Q Growth
-116.43% 1,182.61% 37.35% -13.16% -151.18% -672.37% 134.75% -18.14% 32.63% -37.25% -369.06%
Operating Cash Flow Q/Q Growth
59.69% 24.00% 20.34% -0.04% 7.83% -79.33% 434.15% -23.62% 12.60% 1.84% 21.75%
Free Cash Flow Firm Q/Q Growth
17.98% 84.97% -63.65% 286.50% -34.64% -166.93% 611.90% -88.92% 29.14% 135.42% -88.40%
Invested Capital Q/Q Growth
-3.00% -1.32% 2.37% -6.01% -3.31% 6.19% -1.70% -0.53% -3.07% -0.84% -0.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
89.41% 89.27% 89.42% 88.17% 88.35% 88.88% 88.56% 87.18% 87.45% 90.37% 91.10%
EBITDA Margin
25.27% 35.45% 40.26% 32.43% 12.11% -49.17% 20.94% 36.15% 48.69% 35.36% -18.87%
Operating Margin
7.34% 19.48% 24.67% 17.53% -6.23% -65.64% 5.11% 21.25% 31.49% 20.54% -33.26%
EBIT Margin
7.15% 19.53% 24.60% 16.95% -6.25% -65.81% 5.12% 21.19% 31.72% 20.53% -33.26%
Profit (Net Income) Margin
-1.62% 16.46% 20.39% 17.56% -10.31% -68.71% 22.33% 16.98% 27.42% 15.96% -38.89%
Tax Burden Percent
912.48% 122.22% 107.10% 143.46% 84.27% 97.68% 2,782.65% 97.59% 97.96% 91.37% 105.34%
Interest Burden Percent
-2.48% 68.98% 77.38% 72.22% 195.72% 106.88% 15.68% 82.12% 88.23% 85.05% 111.01%
Effective Tax Rate
0.00% -22.22% -7.24% -43.47% 0.00% 0.00% -2,683.17% 2.38% 2.04% 8.58% 0.00%
Return on Invested Capital (ROIC)
2.55% 12.12% 13.83% 13.63% -2.44% -25.25% 79.18% 12.27% 19.61% 12.05% -15.51%
ROIC Less NNEP Spread (ROIC-NNEP)
1.11% 10.26% 12.15% 11.33% -4.04% -31.67% 39.48% 10.77% 18.21% 10.88% -21.96%
Return on Net Nonoperating Assets (RNNOA)
1.33% 11.36% 12.07% 10.40% -3.42% -31.41% 33.00% 7.70% 11.00% 7.46% -16.20%
Return on Equity (ROE)
3.88% 23.48% 25.90% 24.03% -5.86% -56.65% 112.19% 19.97% 30.61% 19.51% -31.71%
Cash Return on Invested Capital (CROIC)
13.13% 14.82% 9.27% 19.62% 19.45% -1.52% 0.65% -4.55% -1.01% 22.39% 9.96%
Operating Return on Assets (OROA)
2.46% 6.75% 8.37% 5.89% -2.22% -24.11% 1.80% 7.64% 12.04% 8.58% -13.44%
Return on Assets (ROA)
-0.56% 5.69% 6.94% 6.11% -3.67% -25.18% 7.86% 6.12% 10.41% 6.67% -15.71%
Return on Common Equity (ROCE)
3.88% 23.48% 25.90% 24.03% -5.86% -56.65% 112.19% 19.97% 30.61% 19.51% -31.71%
Return on Equity Simple (ROE_SIMPLE)
8.95% 10.50% 11.10% 0.00% 11.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
46 244 279 274 -39 -480 1,601 248 330 227 -289
NOPAT Margin
5.14% 23.81% 26.45% 25.15% -4.36% -45.95% 142.13% 20.74% 30.85% 18.78% -23.28%
Net Nonoperating Expense Percent (NNEP)
1.45% 1.86% 1.68% 2.30% 1.60% 6.43% 39.70% 1.50% 1.39% 1.17% 6.45%
Return On Investment Capital (ROIC_SIMPLE)
- - - 2.68% -0.41% -5.30% 17.17% 2.57% 3.34% 2.48% -2.96%
Cost of Revenue to Revenue
10.59% 10.73% 10.58% 11.83% 11.65% 11.12% 11.44% 12.82% 12.55% 9.63% 8.90%
SG&A Expenses to Revenue
38.99% 33.06% 30.88% 33.94% 57.25% 34.27% 47.12% 33.91% 33.00% 32.21% 32.82%
R&D to Revenue
25.82% 21.56% 18.95% 22.10% 20.12% 104.75% 21.37% 17.86% 18.34% 23.55% 77.72%
Operating Expenses to Revenue
82.07% 69.79% 64.76% 70.64% 94.57% 154.52% 83.45% 65.94% 55.96% 69.83% 124.36%
Earnings before Interest and Taxes (EBIT)
65 200 260 184 -56 -688 58 254 339 248 -413
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
228 363 425 353 109 -514 236 433 521 427 -235
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.05 1.79 1.65 1.82 1.81 1.76 2.02 2.39 2.57 3.15 3.59
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.97 1.72 1.72 1.83 1.85 1.60 1.92 2.42 2.62 3.29 3.19
Price to Earnings (P/E)
22.92 17.04 14.85 13.29 15.64 0.00 0.00 0.00 395.15 16.07 72.97
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
4.36% 5.87% 6.73% 7.52% 6.40% 0.00% 0.00% 0.00% 0.25% 6.22% 1.37%
Enterprise Value to Invested Capital (EV/IC)
1.51 1.40 1.35 1.47 1.48 1.38 1.56 1.83 2.02 2.49 2.57
Enterprise Value to Revenue (EV/Rev)
2.99 2.67 2.60 2.60 2.54 2.50 2.72 3.10 3.18 3.75 3.76
Enterprise Value to EBITDA (EV/EBITDA)
9.83 8.60 7.94 7.72 8.27 27.50 61.69 50.27 20.91 10.68 15.48
Enterprise Value to EBIT (EV/EBIT)
21.95 18.43 15.82 14.91 17.58 0.00 0.00 0.00 0.00 19.22 41.48
Enterprise Value to NOPAT (EV/NOPAT)
15.97 13.98 13.71 12.34 13.03 0.00 0.00 0.00 0.00 14.89 52.49
Enterprise Value to Operating Cash Flow (EV/OCF)
11.05 9.74 8.91 7.57 6.63 7.78 8.13 9.77 10.58 10.40 10.48
Enterprise Value to Free Cash Flow (EV/FCFF)
11.30 9.19 14.65 7.17 7.31 0.00 233.44 0.00 0.00 10.76 25.15
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.54 1.52 1.47 1.49 1.29 1.45 1.35 1.24 1.18 0.91 1.33
Long-Term Debt to Equity
1.38 1.36 1.46 1.48 1.28 1.17 1.09 1.00 0.95 0.69 1.09
Financial Leverage
1.20 1.11 0.99 0.92 0.85 0.99 0.84 0.72 0.60 0.69 0.74
Leverage Ratio
3.18 3.10 3.06 2.99 2.90 2.99 2.90 2.81 2.69 2.59 2.87
Compound Leverage Factor
-0.08 2.14 2.37 2.16 5.68 3.19 0.46 2.31 2.37 2.20 3.18
Debt to Total Capital
60.71% 60.27% 59.44% 59.87% 56.25% 59.14% 57.52% 55.37% 54.16% 47.54% 57.06%
Short-Term Debt to Total Capital
6.44% 6.40% 0.30% 0.30% 0.32% 11.34% 11.04% 10.64% 10.42% 11.10% 10.42%
Long-Term Debt to Total Capital
54.27% 53.87% 59.14% 59.57% 55.92% 47.80% 46.48% 44.73% 43.74% 36.44% 46.63%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
39.30% 39.73% 40.56% 40.13% 43.75% 40.86% 42.48% 44.63% 45.84% 52.46% 42.94%
Debt to EBITDA
4.89 4.70 4.68 4.46 4.30 14.41 29.24 20.34 7.93 2.69 4.86
Net Debt to EBITDA
3.33 3.07 2.67 2.28 2.24 9.92 18.08 11.07 3.67 1.33 2.37
Long-Term Debt to EBITDA
4.37 4.20 4.65 4.44 4.27 11.65 23.63 16.43 6.40 2.06 3.97
Debt to NOPAT
7.95 7.63 8.08 7.14 6.77 -26.31 -15.50 -17.79 -202.69 3.75 16.48
Net Debt to NOPAT
5.42 4.98 4.62 3.64 3.53 -18.12 -9.59 -9.68 -93.89 1.86 8.03
Long-Term Debt to NOPAT
7.10 6.82 8.04 7.10 6.73 -21.26 -12.53 -14.37 -163.68 2.88 13.47
Altman Z-Score
1.27 1.27 1.34 1.44 1.38 0.87 1.24 1.56 1.77 2.27 1.69
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.27 2.37 4.26 4.46 3.38 1.62 1.65 1.86 2.04 1.78 1.82
Quick Ratio
1.62 1.72 3.24 3.57 2.64 1.15 1.24 1.46 1.65 1.38 1.47
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
343 634 230 891 582 -390 1,995 221 286 672 78
Operating Cash Flow to CapEx
3,870.64% 4,672.85% 3,696.21% 2,999.77% 3,096.20% 10.20% 3,127.62% 2,167.00% 0.00% 2,296.69% 59.75%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.34 0.35 0.34 0.35 0.36 0.37 0.35 0.36 0.38 0.42 0.40
Accounts Receivable Turnover
5.78 5.98 5.91 5.72 5.98 5.79 5.59 5.52 5.96 5.77 5.76
Inventory Turnover
0.64 0.69 0.74 0.83 0.85 0.88 0.94 1.12 1.15 1.12 1.10
Fixed Asset Turnover
19.52 19.62 20.02 23.72 23.56 23.07 22.76 22.87 23.24 23.18 22.81
Accounts Payable Turnover
3.90 4.24 4.35 4.94 5.14 4.95 4.03 5.03 5.44 4.89 1.93
Days Sales Outstanding (DSO)
63.20 61.07 61.77 63.80 61.06 63.06 65.31 66.18 61.23 63.26 63.36
Days Inventory Outstanding (DIO)
567.83 527.88 495.19 441.18 429.36 414.51 389.96 325.41 318.65 324.66 332.34
Days Payable Outstanding (DPO)
93.62 86.03 84.00 73.96 70.98 73.78 90.64 72.50 67.11 74.61 188.86
Cash Conversion Cycle (CCC)
537.42 502.93 472.96 431.03 419.44 403.78 364.63 319.09 312.77 313.30 206.85
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
7,583 7,483 7,660 7,200 6,961 7,392 7,266 7,227 7,006 6,947 6,899
Invested Capital Turnover
0.50 0.51 0.52 0.54 0.56 0.55 0.56 0.59 0.64 0.64 0.67
Increase / (Decrease) in Invested Capital
-296 -390 49 -617 -621 -91 -394 27 44 -445 -367
Enterprise Value (EV)
11,473 10,454 10,374 10,561 10,335 10,235 11,310 13,246 14,118 17,271 17,742
Market Capitalization
7,581 6,728 6,880 7,445 7,540 6,540 7,995 10,330 11,638 15,119 15,029
Book Value per Share
$59.11 $59.69 $67.54 $67.72 $68.74 $60.14 $65.27 $71.07 $73.62 $76.53 $64.57
Tangible Book Value per Share
($52.43) ($48.43) ($44.98) ($39.34) ($37.93) ($47.16) ($40.13) ($31.93) ($23.98) ($16.38) ($27.49)
Total Capital
9,407 9,469 10,283 10,202 9,542 9,070 9,320 9,677 9,887 9,153 9,761
Total Debt
5,710 5,707 6,112 6,109 5,367 5,364 5,361 5,358 5,355 4,351 5,569
Total Long-Term Debt
5,105 5,101 6,081 6,078 5,336 4,336 4,332 4,328 4,324 3,335 4,552
Net Debt
3,892 3,726 3,494 3,116 2,796 3,694 3,315 2,916 2,480 2,152 2,713
Capital Expenditures (CapEx)
6.90 7.09 11 13 14 871 15 17 -103 18 847
Debt-free, Cash-free Net Working Capital (DFCFNWC)
765 751 773 629 364 638 465 512 493 554 241
Debt-free Net Working Capital (DFNWC)
2,583 2,731 3,391 3,621 2,936 2,308 2,511 2,953 3,367 2,754 3,098
Net Working Capital (NWC)
1,978 2,126 3,360 3,590 2,905 1,279 1,482 1,924 2,337 1,737 2,080
Net Nonoperating Expense (NNE)
61 75 64 83 53 238 1,349 45 37 34 194
Net Nonoperating Obligations (NNO)
3,886 3,720 3,489 3,106 2,787 3,686 3,307 2,909 2,473 2,145 2,707
Total Depreciation and Amortization (D&A)
163 163 165 168 165 174 178 179 181 179 179
Debt-free, Cash-free Net Working Capital to Revenue
19.90% 19.20% 19.37% 15.45% 8.96% 15.61% 11.18% 11.99% 11.10% 12.04% 5.11%
Debt-free Net Working Capital to Revenue
67.21% 69.86% 84.94% 89.00% 72.23% 56.47% 60.39% 69.21% 75.86% 59.85% 65.65%
Net Working Capital to Revenue
51.46% 54.37% 84.16% 88.24% 71.47% 31.30% 35.64% 45.07% 52.64% 37.76% 44.09%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.23) $2.68 $3.50 $3.11 ($1.52) ($11.74) $4.14 $3.28 $4.73 $3.05 ($7.48)
Adjusted Weighted Average Basic Shares Outstanding
62.54M 62.88M 61.41M 61.84M 60.98M 61.19M 60.70M 60.98M 61.90M 63.20M 64.70M
Adjusted Diluted Earnings per Share
($0.23) $2.49 $3.42 $2.97 ($1.52) ($11.74) $4.08 $3.34 $4.43 $2.78 ($7.48)
Adjusted Weighted Average Diluted Shares Outstanding
62.54M 69.63M 63.17M 66.01M 60.98M 61.19M 61.61M 60.98M 66.10M 69.40M 64.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
63.04M 61.75M 60.45M 60.73M 61.63M 60.66M 60.77M 61.56M 62.74M 64.91M 64.19M
Normalized Net Operating Profit after Tax (NOPAT)
46 140 182 134 -39 -480 40 248 209 227 -289
Normalized NOPAT Margin
5.14% 13.64% 17.27% 12.27% -4.36% -45.95% 3.57% 20.74% 19.59% 18.78% -23.28%
Pre Tax Income Margin
-0.18% 13.47% 19.03% 12.24% -12.23% -70.34% 0.80% 17.40% 27.99% 17.46% -36.92%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 84.98% 88.79% 55.60% 0.00% -67.93% -33.93% -35.10% 0.00% 0.00% 109.26%

Financials Breakdown Chart

Key Financial Trends

Jazz Pharmaceuticals’ (NASDAQ:JAZZ) latest financial statements show a substantial recovery from the pressure seen in 2025. Revenue, profitability and operating cash flow have strengthened, while the company has reduced debt. However, Jazz remains highly dependent on intangible assets and continues to carry significant leverage.

  • Revenue growth has accelerated. Second-quarter 2026 revenue reached $1.21 billion, up 15.6% from $1.05 billion in the restated second quarter of 2025 and up from $972.1 million in the second quarter of 2023. Revenue also increased sequentially from $1.07 billion in the first quarter of 2026.
  • Profitability has rebounded sharply. Jazz reported $248.2 million of operating income and $192.8 million of net income in Q2 2026, compared with an operating loss of $686.4 million and a net loss of $718.5 million in Q2 2025. The prior-year results were heavily affected by unusually high research and development expense and special charges.
  • Gross margins remain very strong. Gross profit was $1.09 billion in Q2 2026, representing a gross margin of approximately 90.4%. This compares favorably with roughly 88.9% in Q2 2025 and 89.2% in Q2 2024, indicating that revenue growth has not materially weakened the company’s product economics.
  • Operating cash flow has improved materially. Cash generated from operations was $415.7 million in Q2 2026, compared with $88.9 million in Q2 2025. Operating cash flow has remained positive in every reported quarter in the data set, including $408.2 million in Q1 2026 and $474.6 million in Q3 2025.
  • Debt reduction is a meaningful recent development. Jazz repaid approximately $1.01 billion of debt during Q2 2026. Total short- and long-term debt declined to approximately $4.35 billion at June 30, 2026, from $5.36 billion a year earlier and $5.35 billion at the end of Q1 2026.
  • Liquidity remains substantial despite the debt repayment. Jazz held $1.62 billion of cash and equivalents plus $580 million of short-term investments at the end of Q2 2026, or approximately $2.20 billion in readily available funds. Current assets of $3.97 billion exceeded current liabilities of $2.23 billion.
  • Research spending has normalized, but investors should monitor the trend. Q2 2026 research and development expense was $284.5 million, well below the restated $1.10 billion reported in Q2 2025, but higher than $209.2 million in Q2 2023 and $220.7 million in Q2 2024. The comparison suggests a return to more typical spending levels after an unusually large prior-year charge.
  • Cash flow benefited from investment maturities. Q2 2026 investing cash flow was positive at $354.9 million because Jazz received $720 million from investment sales or maturities, partially offset by $270 million of investment purchases, $77 million of acquisitions and $18.1 million of capital expenditures. This source of cash may not be recurring operating cash generation.
  • Jazz’s balance sheet remains asset-heavy. Goodwill and intangible assets totaled approximately $5.83 billion at June 30, 2026, or more than half of total assets. The company has recorded substantial amortization expense—$170 million in Q2 2026—which reduces reported operating income and highlights the importance of maintaining the value of acquired products and businesses.
  • Leverage and financing costs continue to weigh on earnings. Despite recent debt repayment, total liabilities were $6.28 billion compared with $4.80 billion of equity. Net interest and investment expense was approximately $37.1 million in Q2 2026, limiting the conversion of operating income into pretax profit.

Overall, Jazz’s recent trend is improving: revenue is growing, operating margins have recovered and operating cash flow is consistently positive. The largest risks for investors are the company’s reliance on intangible assets, ongoing amortization and the need to sustain cash generation while continuing to reduce debt.

11/16/26 07:40 PM ETAI Generated. May Contain Errors.

Jazz Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Jazz Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Jazz Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$356.15 million in 2025, compared with $329.53 million in 2015. The previous period was $560.12 million in 2024. View Jazz Pharmaceuticals' forecast to see where analysts expect Jazz Pharmaceuticals to go next.

Jazz Pharmaceuticals' total operating income in 2025 was -$430.24 million, based on the following breakdown:
  • Total Gross Profit: $3.76 billion
  • Total Operating Expenses: $4.19 billion

Over the last 10 years, Jazz Pharmaceuticals' total revenue changed from $1.32 billion in 2015 to $4.27 billion in 2025, a change of 222.1%.

In the past 13 quarters, Jazz Pharmaceuticals' cash and equivalents has ranged from $1.19 billion in Q2 2025 to $2.22 billion in Q3 2024, and is currently $2.04 billion as of their latest financial filing in Q3 2026.

Jazz Pharmaceuticals had total debt of $5.36 billion at the end of 2025, a 12.3% decrease from 2024, and a 350.9% increase since 2015.

Over the last 10 years, Jazz Pharmaceuticals' book value per share changed from 26.00 in 2015 to 71.07 in 2025, a change of 173.4%.



Financial statements for NASDAQ:JAZZ last updated on 11/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners